The Role Of Immunodeficient Animal Models In Advancing Immuno-Oncology Research By Dr Michael Seiler From inbred wild-type to more advanced genetically-engineered strains, mouse models enable researchers to gain important insights into the complex biological underpinnings of human cancer. Read More
Chimeric Antigen Receptor T-cells (CAR-T): Looking beyond the hype By Christoph Oldenburg, Dr Markus Thunecke and Dr John Herrmann While Chimeric Antigen Receptor T-cells (CAR-T), have already demonstrated convincing efficacy in a specific setting, the jury is still out on whether they are a ‘game-changer’ for oncology as… Read More
Phenotypic Drug Discovery: Striving towards the highest level of biological relevance By Dr John Comley Phenotypic drug discovery (PDD) implies screening where the molecular mechanism of action is not assumed and does not require knowledge of the molecular target. As such phenotypic… Read More
The Increasing Impact of Precision Research Models on Drug Discovery and Development Dr Amar Thyagarajan Animal models are the standard by which we gain insight into the complex biological processes that underlie normal human physiology and disease states. Rodent models such as rats and mice have been used… Read More
New Developments in Single Cell Separation and Analysis Technologies By Dr John Comley Drug Discovery Recent advances of single cell technologies are facilitating the opportunity to discern biological insights within individual cells and providing a means to reveal previously hidden relationships between individual cells within a population. Read More
Misconduct in the biomedical sciences part 2: detection and prevention By Dr Gerald H. Lushington and Rathnam Chaguturu Discovering safe and effective medicines, one of the greatest gifts to humanity, relies intensely upon the availability of detailed, unassailably accurate biomedical scientific knowledge. The… Read More
Adoptive T-Cell Therapies: unlocking the potential of engineered antigen receptors By Dr Cenk Sumen, Dr Dan Williams and Dr Gwendolyn Binder-Scholl T-cells with engineered receptors to target tumours represent living drugs with enormous potential in the fight against cancer, but many challenges remain to be overcome in order… Read More
Precise genome editing: the key to a CRISPR drug discovery pipeline? By Dr. J. D. Wrigley, Dr M Maresca, Dr K Birmingham, Dr M Bohlooly-Y and Dr L M. Mayr From the pioneering days of Watson and Crick in 1953, to completion of the human genome project in… Read More
Immunotherapy: The coming of age of cancer immunotherapy as a treatment paradigm By Dr Jean Pierre Wery As the oncology drug development landscape has evolved, so too have the processes, methods and equipment used in the fight against cancer. Traditional treatments such as chemotherapy and radiation therapy are… Read More
Advancing the Promise of Therapeutic Genomic Editing By Dr Morgan L. Maeder and Dr David Bumcrot The development of genome editing technology is revolutionising the study of gene function and has the potential to usher in a new class of therapeutics for a broad range of diseases. Read More
Oncology Target Discovery by RNAi: The past, present, and future perspectives By Dr Hakim Djaballah and Bhavneet Bhinder Despite an investment of billions of US dollars in the search of novel therapies, cancer still remains the leading cause of death in the world. This emphasises the need… Read More
The CRISPR/Cas9 System: Cutting a path for rapid generation of more translational animal models. By Dr Kevin M. Gamber The recent high-profile translational failures in mouse models have highlighted the need for more relevant animal models. Advances in gene editing tools, including the CRISPR/Cas9 system, have enabled the… Read More
Gene Editing: Re-writing Genomes With Targetable Nucleases By Dr Dana Carroll We are in the midst of a revolution in genome engineering, based on reagents that can be designed to cut chromosomal DNA at arbitrary sites. These targetable nucleases allow creation of new mutations at specific sites,… Read More
The Great Neuro-Pipeline Brain Drain – Why Big Pharma Hasn’t Given Up On CNS Disorders By Julia Skripka-Serry Central Nervous System (CNS) disorders bear an economic burden of more than $2 trillion in the US and EU and rake in upwards of $80 billion a year for the… Read More
Stem Cells Rapidly Gaining Traction in Research and Drug Discovery By Dr John Comley A recent market survey on stem cells in research and drug discovery showed that despite a significant amount of hype and hope around stem cells, most drug discovery-related efforts today still fall into the… Read More
By Dr Nikolai Schwabe and Katherine Catchpole T cells play a crucial role in building a specialised immune response and help adapt the immune response to different challenges, whether they are intracellular bacteria, viruses or cancer or extracellular organisms such as blood-borne bacteria and… Read More